Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18416949 | 0.77 | CYP2D6 (0.42) | CYP2D6SMN1; SMN2CYP1A2HIF1AUSP2 | |
| SCHEMBL23344772 | 0.74 | — | — | |
| SCHEMBL23344764 | 0.74 | — | — | |
| SCHEMBL9882953 | 0.74 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2CYP1A2HIF1AUSP2 | |
| SCHEMBL23344771 | 0.71 | TP53 (0.32) | — | |
| SCHEMBL19596790 | 0.70 | CYP2D6 (0.32) | CYP2D6SMN1; SMN2CYP1A2HIF1AUSP2 | |
| SCHEMBL24597148 | 0.70 | TP53 (0.32) | CYP2D6SMN1; SMN2CYP1A2HIF1AUSP2 | |
| SCHEMBL24597153 | 0.70 | ALDH1A1 (0.32) | CYP2D6SMN1; SMN2CYP1A2HIF1AUSP2 | |
| SCHEMBL23344769 | 0.70 | CYP2D6 (0.31) | CYP2D6 | |
| SCHEMBL15461408 | 0.67 | CYP2D6 (0.35) | CYP2D6SMN1; SMN2CYP1A2HIF1AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP2D6 1282/4885SMN1; SMN2 432/4885CYP1A2 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.